Connor Clark & Lunn Investment Management Ltd. Invests $2.35 Million in Hologic, Inc. (NASDAQ:HOLX)

Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 28,847 shares of the medical equipment provider's stock, valued at approximately $2,350,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. The Manufacturers Life Insurance Company boosted its holdings in Hologic by 21.6% in the second quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider's stock worth $188,243,000 after purchasing an additional 450,190 shares during the last quarter. Black Creek Investment Management Inc. boosted its stake in shares of Hologic by 60.9% during the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider's stock worth $173,669,000 after acquiring an additional 885,524 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Hologic by 5.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider's stock worth $172,780,000 after acquiring an additional 124,739 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in shares of Hologic by 4.0% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,271,603 shares of the medical equipment provider's stock worth $168,666,000 after acquiring an additional 87,176 shares during the last quarter. Finally, Hsbc Holdings PLC boosted its stake in shares of Hologic by 14.6% during the 2nd quarter. Hsbc Holdings PLC now owns 2,034,651 shares of the medical equipment provider's stock worth $151,100,000 after acquiring an additional 259,185 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Hologic Price Performance

NASDAQ HOLX traded down $0.73 on Tuesday, reaching $79.00. The company had a trading volume of 1,922,089 shares, compared to its average volume of 1,595,139. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $18.35 billion, a PE ratio of 23.72, a price-to-earnings-growth ratio of 2.49 and a beta of 0.98. The firm's 50 day moving average price is $80.38 and its 200 day moving average price is $78.38. Hologic, Inc. has a 12 month low of $67.59 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.01. The company had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. Hologic's revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.89 EPS. As a group, equities analysts predict that Hologic, Inc. will post 4.27 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on HOLX shares. Mizuho dropped their price target on shares of Hologic from $90.00 to $87.00 and set an "outperform" rating on the stock in a research note on Tuesday, November 5th. Leerink Partners dropped their price target on shares of Hologic from $95.00 to $90.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 8th. StockNews.com upgraded shares of Hologic from a "hold" rating to a "buy" rating in a research note on Thursday, November 14th. Evercore ISI lifted their target price on shares of Hologic from $78.00 to $82.00 and gave the company an "in-line" rating in a research note on Tuesday, October 1st. Finally, Stephens restated an "overweight" rating and set a $92.00 target price on shares of Hologic in a research note on Tuesday, July 30th. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $89.91.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.